e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2008
QUESTCOR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
         
California
(State or Other Jurisdiction
of Incorporation)
  001-14758
(Commission File Number)
  33-0476164
(I.R.S. Employer
Identification No.)
     
3260 Whipple Road Union City, California
(Address of Principal Executive Offices)
  94587
(Zip Code)
Registrant’s telephone number, including area code: (510) 400-0700
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


TABLE OF CONTENTS

Item 8.01 Other Events.
SIGNATURES


Table of Contents

Item 8.01   Other Events.
     On November 6 and 7, 2008, Don Bailey, the President and Chief Executive Officer of Questcor Pharmaceuticals, Inc. (the “Company”) since May 2007, completed the exercise and same-day sale of 341,661 options to purchase shares of common stock of the Company at prices ranging from $8.50 to $8.75 per share. Mr. Bailey exercised these options for portfolio diversification purposes. After completion of the exercises and same-day sales, Mr. Bailey’s combined position in both shares of common stock of the Company and options to purchase shares of common stock of the Company totaled approximately one million shares and options.

 


Table of Contents

SIGNATURES
     Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: November 7, 2008  QUESTCOR PHARMACEUTICALS, INC.

 
 
  By:   /s/ Gary M. Sawka    
    Gary M. Sawka   
    Senior Vice President of Finance, and
Chief Financial Officer